人胰高血糖素样肽-1与人血清白蛋白融合蛋白在毕赤酵母中的表达

目的：在巴斯德毕赤酵母中表达有降糖活性的人胰高血糖素样肽-1（hGLP-1）突变体（2Gly-hGLP-1）与人血清白蛋白（HSA）的融合蛋白。方法：为将GLP-1氨基酸序列第2位的丙氨酸（Ala）定点突变为甘氨酸（Gly）,根据毕赤酵母偏爱密码子合成编码2Gly-hGLP-1的基因;采用重叠PCR法拼接2Gly-hGLP-1和HSA的基因,使得2Gly-hGLP-1的C端与HSA的N端通过甘氨酸五肽接头连接;将该融合基因插入表达载体pPIC9构建为重组载体pPIC9/2Gly-hGLP-1-HSA,电击转化至毕赤酵母GS115细胞,通过表型筛选和诱导表达实验获得高效表达菌株;工程菌在5L发酵罐中培养后,对发酵产物进行分离纯化和生物学活性分析。结果：融合蛋白在5L发酵罐中的表达量约为200mg/L,经纯化后纯度可达95%以上;小鼠糖耐量实验表明该融合蛋白具有明显的控血糖活性。结论：在毕赤酵母中分泌表达的融合蛋白2Gly-hGLP-1-HSA具有降血糖活性。     

鸡α干扰素在毕赤酵母中的表达及糖基化对其表达的影响

目的:实现鸡α干扰素(ChIFNα)在毕赤酵母GS115中的表达,并考察糖基化对其表达的影响。方法:人工合成按照毕赤酵母偏好密码子优化的ChIFNα基因,克隆至分泌表达载体pPIC9,电转到毕赤酵母GS115中进行表达。利用定点突变对ChIFNα基因序列中4个糖基化位点进行缺失,SDS-PAGE分析N-糖基化对毕赤酵母表达ChIFNα的影响。结果:ChIFNα在GS115中获得了表达,在摇瓶发酵条件下,表达量为35.2 mg/L;构建了缺失1~4个糖基化位点的4个突变体,在GS115中实现了表达,分析表达结果显示,与未突变的ChIFNα对照相比,突变体的糖基化程度和表达量都有大幅度下降。结论:N-糖基化对于毕赤酵母表达ChIFNα具有重要影响,无糖基化的ChIFNα在毕赤酵母中表达量极低。     

金针菇免疫调节蛋白基因fip-fve在毕赤酵母GS115中诱导型和组成型表达

为获得稳定来源并且具有生物学活性的重组金针菇免疫调节蛋白(Fip-fve),将fip-fve基因转至毕赤酵母GS115中进行诱导型和组成型表达。用PCR方法从金针菇子实体基因组DNA中扩增fip-fve基因,连接至pPIC9构建诱导型表达载体pPIC9-FIP-fve,从毕赤酵母基因组DNA中扩增三磷酸甘油醛脱氢酶启动子(pgap),替换pPIC9-FIP-fve上乙醇氧化酶启动子(paox1)构建组成型表达载体pPIC9-PGAP-FIP-fve。将线性化的两种表达载体用PEG法转化毕赤酵母GS115,经组氨酸缺失培养基筛选和酵母菌落PCR鉴定后进行表达。结果表明,重组Fip-fve在以甲醇(1%,V/V)为碳源进行诱导型表达4 d达到最高,粗蛋白表达量为158.2 mg/L,在以葡萄糖(10%)和甘油(1%,V/V)为碳源进行组成型分别在表达第4天和第5天达到最高,粗蛋白分别为46.3 mg/L和29.5 mg/L。SDS-PAGE及Western blotting证明重组Fip-fve已正确表达,血细胞凝集活性检测初步证明重组Fip-fve具有良好生物学活性。     

用P.pastoris表达L-阿拉伯糖异构酶及其酶活性分析

目的:用毕赤酵母表达L-阿拉伯糖异构酶。方法:用PCR法扩增大肠杆菌的L-阿拉伯糖异构酶基因,构建含L-阿拉伯糖异构酶基因的毕赤酵母分泌型表达载体pPIC9K-ai。通过电转法将pPIC9K-ai转化毕赤酵母GS115基因组。先筛选出高G418抗性的克隆,然后再从高拷贝的克隆中筛选出高表达重组L-阿拉伯糖异构酶的重组子作为工程菌GS115(pPIC9K-ai)。结果:在甲醇诱导下,摇瓶发酵GS115(pPIC9K-ai)3d,分泌表达L-阿拉伯糖异构酶32 mg/L。结论:毕赤酵母表达的L-阿拉伯糖异构酶具有转化D-半乳糖为D-塔格糖的生物活性。每升GS115(pPIC9K-ai)发酵液能转化D-半乳糖生成30 mgD-塔格糖。     

用毕赤酵母组成型分泌表达Canstatin-N

目的:用毕赤酵母的GAP启动子调控组成型表达Canstatin-N。方法:将canstatin-N基因重组于毕赤酵母表达载体pGAP9K的多克隆位点获得pGAP9K-can-N。用电转法将pGAP9K-can-N转化毕赤酵母GS115。筛选高G418抗性的克隆作为工程菌GS115(pGAP9K-can-N)。发酵GS115(pGAP9K-can-N)分泌表达Canstatin-N,用离子交换法纯化目标蛋白。结果:以葡萄糖为碳源,发酵48h分泌表达人血管能抑素蛋白56 mg/L。结论:用毕赤酵母的GAP启动子调控组成型表达的人血管能抑素蛋白具有诱发血管内皮细胞凋亡的生物活性。     

人精氨酸酶在毕赤酵母的高效表达、纯化和活性研究

目的：人精氨酸酶（Arginase, Arg）的基因arg在毕赤酵母高效分泌表达,建立相应纯化工艺路线,研究重组人精氨酸酶的活性。方法：将人精氨酸酶基因arg按正确的阅读框架插入到毕赤酵母表达载体pPIC9α信号肽基因后,构建得到重组毕赤酵母表达质粒。转化毕赤酵母GS115筛选高表达菌株。结果：成功构建了酵母表达载体pPIC-Arg,转化毕赤酵母GS115后筛选到分泌表达目的蛋白Arg的菌株,目标蛋白可以分泌到培养基中。经过膜过滤和凝胶过滤层析对培养基上清进行纯化,即可获得纯度达到95%的活性产物。活性测定表明,纯化的Arg比活性为310 IU/mg。结论：成功构建了Arg的毕赤酵母高效表达菌种,建立了目标物质的分离纯化工艺。     

HPV18晚期蛋白L1在毕赤酵母菌中的表达及鉴定

目的:用毕赤酵母胞内表达载体构建含人乳头瘤病毒18型(HPV18)L1基因质粒,诱导表达并进行鉴定。方法:按照毕赤酵母密码子偏爱性原则,合成全长L1基因,然后克隆到pAO819表达载体上,在体外分别构建含一个拷贝和二个拷贝的L1基因载体。线形化后转化到GS115酵母细胞,经G418抗性筛选,获高拷贝重组子并经甲醇诱导表达,表达产物采用化学发光Western blot鉴定,一抗为抗HPV18L1蛋白鼠抗血清。结果:在55kDa处有诱导蛋白免疫印迹出现,并在电镜下观察到HPV18的病毒样颗粒(VLPs),证明该表达系统能表达出HPV18 L1蛋白。结论:本实验构建的毕赤酵母表达菌株,可经甲醇诱导表达HPV18L1晚期蛋白,为进一步研制人乳头瘤病毒18型基因工程疫苗打下基础。     

猪IL-18在毕赤酵母中的表达及活性分析

采用PCR方法从pGEM-IL-18重组质粒中扩增出IL-18基因并构建真核融合表达载体pPIC9K-IL-18,电激法转化入毕赤酵母GS115,采用G418抗性梯度法筛选得到多拷贝重组菌株,甲醇诱导表达,应用SDS-PAGE分析重组蛋白的表达情况,并将表达蛋白用凝胶层析柱纯化后,用MTT法检测其生物学活性。实验结果表明重组的GS115酵母菌株可表达分泌pIL-18,其表达在72h时达高峰,分泌量可达160mg/L,纯化的重组pIL-18蛋白具有显著的促进淋巴细胞增殖的活性,说明本试验已在毕赤酵母中在国内首次成功表达了具有生物学活性的pIL-18。     

用毕赤酵母的GAP启动子调控表达L-阿拉伯糖异构酶

应用PCR从大肠杆菌基因组中扩增L-阿拉伯糖异构酶基因,用EcoR I和Not I双酶切将其克隆进P.pastoris表达载体,获得重组表达载体pGAP9K-L-ai。通过电转法将pGAP9K—L-ai转化毕赤酵母GS115,筛选高G418抗性和高表达L-阿拉伯糖异构酶的重组工程菌。用葡萄糖作为碳源在摇瓶中发酵48 h,表达重组L-ai 53 mg/L。用毕赤酵母的GAP启动子调控表达的重组L-ai具有异构D-半乳糖生成D-塔格糖的生物学活性。     

N-糖基化对毕赤酵母表达的DSPAα1分泌和活性的影响(英文)

溶栓剂DSPAα1正处于治疗急性缺血性中风的III期临床研究,临床结果显示DSPAα1具有良好的药理学和安全特性。将DSPAα1基因序列按照毕赤酵母偏好密码子进行优化,并在毕赤酵母菌株GS115和KM71中进行表达,同时利用定点突变对糖基化侧链进行缺失,考察糖基侧链对毕赤酵母表达DSPAα1的影响。结果表明,野生型DSPAα1在GS115和KM71中均获得高表达,在摇瓶发酵条件下,表达量分别为70mg/L和105mg/L;利用SDS-PAGE对DSPAα1三种突变体(N117Q、N362Q和N117Q/N362Q)进行分析,与野生型蛋白质相比较,3种突变体的表达水平显著下降,同时纤溶平板测活数据显示,纯化后的突变体N117Q和N362Q比活性均低于野生型蛋白质的25%。这表明,N-型糖链(N117和N362)对毕赤酵母表达的DSPAα1分泌和酶活性具有重要作用。     

Structure-activity analysis of the dermcidin-derived peptide DCD-1L, an anionic antimicrobial peptide present in human sweat

Dermcidin encodes the anionic amphiphilic peptide DCD-1L, which displays a broad spectrum of antimicrobial activity under conditions resembling those in human sweat. Here, we have investigated its mode of antimicrobial activity. We found that DCD-1L interacts preferentially with negatively charged bacterial phospholipids with a helix axis that is aligned flat on a lipid bilayer surface. Upon interaction with lipid bilayers DCD-1L forms oligomeric complexes that are stabilized by Zn(2+). DCD-1L is able to form ion channels in the bacterial membrane, and we propose that Zn(2+)-induced self-assembly of DCD-1L upon interaction with bacterial lipid bilayers is a prerequisite for ion channel formation. These data allow us for the first time to propose a molecular model for the antimicrobial mechanism of a naturally processed human anionic peptide that is active under the harsh conditions present in human sweat.     

Expression and purification of human antimicrobial peptide, dermcidin, in Escherichia coli

Human dermcidin, an anionic antimicrobial peptide expressed in the pons of the brain and the sweat glands, displays antimicrobial activity against pathogenic microorganisms such as Staphylococcus aureus and Candida albicans. Here, we describe the recombinant production of a 48 amino acid dermcidin variant with C-terminal homoserine lactone (DCD-1Hsl). Dermcidin coding sequence was cloned downstream of a 125 amino acid ketosteroid isomerase gene and upstream of a His6Tag sequence in pET-31b(+) vector and transformed into Escherichia coli. The fusion protein was expressed in the form of inclusion bodies, purified on His Bind Resin, and cleaved by CNBr to release recombinant DCD-1Hsl. Purification of rDCD-1Hsl was achieved by solid-phase extraction that yielded milligram amounts of peptide with more than 95% purity. Recombinant peptide showed antimicrobial activities against E. coli ML-35p, Salmonella typhimurium 5156, Listeria monocytogenes 264, S. aureus 29/58 (clinical isolate), and C. albicans K2 (clinical strain). The application of this expression/purification approach represents a fast and efficient method to prepare milligram quantities of dermcidin in its biologically active form.     

Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo

Antimicrobial peptides are an integral part of the epithelial innate defense system. Dermcidin (DCD) is a recently discovered antimicrobial peptide with a broad spectrum of activity. It is constitutively expressed in human eccrine sweat glands and secreted into sweat. Patients with atopic dermatitis (AD) have recurrent bacterial or viral skin infections and pronounced colonization with Staphylococcus aureus. We hypothesized that patients with AD have a reduced amount of DCD peptides in sweat contributing to the compromised constitutive innate skin defense. Therefore, we performed semiquantitative and quantitative analyses of DCD peptides in sweat of AD patients and healthy subjects using surface-enhanced laser desorption ionization time-of-flight mass spectrometry and ELISA. The data indicate that the amount of several DCD-derived peptides in sweat of patients with AD is significantly reduced. Furthermore, compared with atopic patients without previous infectious complications, AD patients with a history of bacterial and viral skin infections were found to have significantly less DCD-1 and DCD-1L in their sweat. To analyze whether the reduced amount of DCD in sweat of AD patients correlates with a decreased innate defense, we determined the antimicrobial activity of sweat in vivo. We showed that in healthy subjects, sweating leads to a reduction of viable bacteria on the skin surface, but this does not occur in patients with AD. These data indicate that reduced expression of DCD in sweat of patients with AD may contribute to the high susceptibility of these patients to skin infections and altered skin colonization.     

Cathepsin D is present in human eccrine sweat and involved in the postsecretory processing of the antimicrobial peptide DCD-1L

The protein pattern of healthy human eccrine sweat was investigated and 10 major proteins were detected from which apolipoprotein D, lipophilin B, and cathepsin D (CatD) were identified for the first time in human eccrine sweat. We focused our studies on the function of the aspartate protease CatD in sweat. In vitro digestion experiments using a specific fluorescent CatD substrate showed that CatD is enzymatically active in human sweat. To identify potential substrates of CatD in human eccrine sweat LL-37 and DCD-1L, two antimicrobial peptides present in sweat, were digested in vitro with purified CatD. LL-37 was not significantly digested by CatD, whereas DCD-1L was cleaved between Leu(44) and Asp(45) and between Leu(29) and Glu(30) almost completely. The DCD-1L-derived peptides generated in vitro by CatD were also found in vivo in human sweat as determined by surface-enhanced laser desorption/ionization (SELDI) mass spectrometry. Furthermore, besides the CatD-processed peptides we identified additionally DCD-1L-derived peptides that are generated upon cleavage with a 1,10-phenanthroline-sensitive carboxypeptidase and an endoprotease. Taken together, proteolytic processing generates 12 DCD-1L-derived peptides. To elucidate the functional significance of postsecretory processing the antimicrobial activity of three CatD-processed DCD-1L peptides was tested. Whereas two of these peptides showed no activity against Gram-positive and Gram-negative bacteria, one DCD-1L-derived peptide showed an even higher activity against Escherichia coli than DCD-1L. Functional analysis indicated that proteolytic processing of DCD-1L by CatD in human sweat modulates the innate immune defense of human skin.     

Identification of dermcidin in human gestational tissue and characterization of its proteolytic activity

Dermcidin (DCD) is a gene for an antimicrobial peptide DCD-1 in human sweat glands. It has become evident that the gene products of DCD exhibit a wide range of biological functions. In addition to its antimicrobial function, it is reported to be a neuronal survival factor, a putative oncogene in breast cancer and a proteolysis-inducing factor (PIF) that induces skeletal muscle proteolysis to cause cancer cachexia. Here we identified DCD in human placental tissue and determined its previously uncharacterized proteolytic activity. We also show that recombinant DCD induced an invasive phenotype in a human choriocarcinoma cell line JAR in vitro. This work suggests that DCD might participate in the regulation of placental function by means of modulating the proteolytic cascades on the trophoblastic cell surface, and might be involved in the pathophysiology of pregnancy-related disorders, as well as cancer and neuronal diseases.     

阿维链霉菌来源的磷脂酰丝氨酸合成酶基因的克隆及其在毕氏酵母中的异源表达

本文旨在构建阿维链霉菌(Streptomyces avermitilis)来源的磷脂酰丝氨酸合成酶基因(pss)的重组质粒,研究其在毕氏酵母中的异源分泌型表达。利用PCR技术克隆阿维链霉菌来源的pss基因,再通过电转化方法将重组质粒pOG-01转入毕氏酵母KM71中,构建重组工程菌KP1。实验结果表明,阿维链霉菌来源的磷酯酰丝氨酸合成酶基因在毕氏酵母KM71中成功表达,2 mL菌体上清催化50 mmol/L卵磷脂,转酯反应的转化率为58%,酶活为4.83 U/mL。     

Expression of 4kD scorpion defensin and its in vitro synergistic activity with conventional antibiotics

The 4kD scorpion defensin (SD) is a potent disulfide-linked peptide. In this study, we expressed it in methylotrophic yeast Pichia pastoris and purified it using Ni–NTA His Bind Resin. We investigated its in vitro antibacterial activity and effect in combination with several conventional antibiotics. We first examined its antibacterial activity towards several Gram-positive and Gram-negative bacteria. Then we used the broth microdilution method to test drugs alone and in combination and used the fractional inhibitory concentration (FIC index) to classify the drug interactions. Our study showed the expressed SD peptide has antibacterial activity against Salmonella typhimurium, E. coli and S. aureus etc. Synergy or additive interaction was observed between SD and Norfloxacin, Polymyxin B and Ampicillin. Cell growth tests showed that combination of SD and Norfloxacin can improve their activity against bacteria. This result maybe permit lower using of the conventional antibiotic agents more effectively and safely.     

毕赤酵母高效表达血小板源生长因子研究

血小板源生长因子（PDGF）是由多种细胞产生的肽类生长因子,在细胞培养、皮肤溃疡的治疗以及化妆品添加剂中有很重要的作用．将编码PDGF基因克隆到表达载体X1-1-B1ue上,通过电转化整合到毕赤酵母的基因组中,在毕赤酵母三磷酸甘油醛脱氢酶（GAP）启动子的作用下,表达PDGF蛋白,其分子质量为30kD左右,估计其表达量为80～100mg／L．采用MTT法也证实其生物学活性与天然PDGF蛋白非常相似．     

犬细小病毒VP2基因的克隆及其在毕赤酵母中的表达

目的表达犬细小病毒VP2蛋白（CPVVP2）,用于犬细小病毒病的诊断、疫苗研制和VP2蛋白功能研究。方法采用PCR方法对CPVVP2基因进行扩增,将CPVVP2基因克隆到毕赤酵母（Pichiapastoris）分泌表达载体pPICZαA中,构建真核重组表达载体pPICZαA—VP2,将该重组质粒线性化后,转化毕赤酵母菌GS115中,在甲醇诱导下表达CPVVP2,SDS-PAGE和Western blotting鉴定表达蛋白。结果成功扩增了CPVVP2基因,构建了真核重组表达载体pPICZαA-VP2在毕赤酵母菌中表达出约64．35kD蛋白。Western blotting鉴定表明,表达VP2蛋白与犬细小病毒阳性血清有反应性。结论在毕赤酵母中成功地表达了CPVVP2蛋白,能被犬细小病毒阳性血清识别。     

杂合抗菌肽CecA-mil的改造及在毕赤酵母中的分泌表达

参照毕赤氏巴斯德酵母(Pichia pastorts)偏好密码子,改造并化学合成杂合抗菌肽CecA-mil基因,改造后的CecA-mil基因克隆到pPICZα-A载体中,构建分泌型重组酵母表达载体pPICZα-A-CM,转化Pichia pastoris受体菌X-33。在醇氧化酶(AOX)启动子调控下,分子量约1．9kD的CecA-mil杂合抗菌肽获得表达,经表达条件优化,重组酵母菌的摇瓶发酵产率可达到245μg／mL。抗菌特性研究表明,该表达产物具有广谱抗菌活性,对多数G^-菌及G^ 菌均有较好的抑菌活性,特别是对氨苄青霉素抗性菌和卡那霉素抗性菌抑杀效果更好;具有热稳定性和酸稳定性。这些特点使得重组抗菌肽CecA-mil在食品防腐、疾病防治和动物饲料添加剂等方面显露出很好的应用前景。